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Abstract
The catalytic activity of trypsin-like serine proteases is in many cases regulated by confor-
mational changes initiated by binding of physiological modulators to exosites located dis-
tantly from the active site. A trypsin-like serine protease of particular interest is urokinase-
type plasminogen activator (uPA), which is involved in extracellular tissue remodeling pro-
cesses. Herein, we used hydrogen/deuterium exchange mass spectrometry (HDXMS) to
study regulation of activity in the catalytic domain of the murine version of uPA (muPA) by
two muPA specific monoclonal antibodies. Using a truncated muPA variant (muPA16-243),
containing the catalytic domain only, we show that the two monoclonal antibodies, despite
binding to an overlapping epitope in the 37s and 70s loops of muPA16-243, stabilize distinct
muPA16-243 conformations. Whereas the inhibitory antibody, mU1 was found to increase
the conformational flexibility of muPA16-243, the stimulatory antibody, mU3, decreased
muPA16-243 conformational flexibility. Furthermore, the HDXMS data unveil the existence of
a pathway connecting the 70s loop to the active site region. Using alanine scanning muta-
genesis, we further identify the 70s loop as an important exosite for the activation of the
physiological uPA substrate plasminogen. Thus, the data presented here reveal important
information about dynamics in uPA by demonstrating how various ligands can modulate
uPA activity by mediating long-range conformational changes. Moreover, the results provide
a possible mechanism of plasminogen activation.
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Introduction
Urokinase-type plasminogen activator (uPA) is a trypsin-like serine protease that plays a piv-
otal role in fibrinolysis in the extracellular space as initiator of a protein cascade eventually
leading to generation of another trypsin-serine protease, plasmin. Plasmin, in turn, acts
directly to degrade fibrin and indirectly, and relatively nonspecifically, to activate matrix-
metalloproteases which then degrade collagen [1]. Under normal physiological conditions, the
proteolytic activity of uPA is involved in processes such as wound healing. However, under
abnormal pathophysiological conditions, the activity of uPA is implicated in tissue remodeling
in several diseases including rheumatoid arthritis, progression of cancer and atherosclerosis
[2–6].
uPA is a three-domain protein consisting of a receptor binding domain (epidermal growth
factor like domain), a kringle domain, and a catalytic serine protease domain. The serine pro-
tease domain adopts the typical double β-barrel chymotrypsin-like fold containing 6 β-strands
in each β-barrel (the N-terminal β-barrel (β1- β6) and the C-terminal β-barrel (β7- β12))
flanked by 3 α-helices (α1-α3) and 11 connecting loops [7]. uPA is synthesized as a low-activ-
ity single-chain zymogen that is processed by plasmin to a two-chain form. Plasmin cleavage
of single-chain uPA liberates a new N-terminus (Ile16) that becomes inserted into a hydropho-
bic binding cleft referred to as the activation pocket. This results in ordering of several surface-
exposed loops, including the N-terminal activation loop (residues 16–21), the 140s loop (resi-
dues 142–152), the 180s loop (residues 184–194) and the 220s loop (residues 216–223) [8]. As
a result of ordering these loops, the active site of uPA (His57, Asp102 and Ser195) including
the primary S1 substrate-binding pocket (Asp189) and the oxyanion hole defined by the main
chain amides of Gly193 and Ser195, adopts a fully-catalytically active conformation [9].
Trypsin-like serine proteases have very dynamic structures and exist even in their activated
two-chain form as conformational ensembles constantly interconverting between active and
inactive states [10–14]. We have recently determined X-ray crystal structures of the murine
version of uPA (muPA) in an active and an inactive conformation [15]. The active conforma-
tion displayed a catalytically competent state with the N-terminal Ile16 inserted into the activa-
tion pocket and with a correctly assembled oxyanion hole and S1 specificity pocket. The
inactive conformation displayed a catalytically incompetent state with the N-terminal Ile16
solvent-exposed and with disintegrated catalytic machinery.
We have previously identified an exosite in the 37s and 70s loops in the N-terminal β-barrel
of murine uPA (muPA), and showed how the binding of two monoclonal antibodies to this
site affected the activity of muPA differently. Whereas one of the antibodies, mU1, blocked
muPA-mediated plasminogen activation and plasmin-mediated single-chain muPA activation,
the other antibody, mU3, was only blocking muPA-mediated plasminogen activation [16, 17].
Moreover, mU1 but not mU3 was found to inhibit muPA-dependent processes in vivo [18,
19]. It was further shown that mU1 but not mU3 competitively inhibits muPA hydrolysis of a
small tri-peptide chromogenic substrate [16, 17]. These studies also revealed that mU1
remained inhibitory towards a truncated muPA variant that only contained the catalytic serine
protease domain (muPA16-243). Surprisingly, it was further shown that mU3 stimulates the cat-
alytic activity of muPA16-243 by 2-fold (16, 17).
In this study, we sought to investigate the molecular mechanisms behind the differences in
functional effects of mU1 and mU3 to the catalytic activity of muPA16-243 by evaluating the
conformational flexibility of muPA16-243 by hydrogen/deuterium exchange mass spectrometry
(HDXMS) in the absence or presence of mU1, mU3 or the active site binding ligand Glu-Gly-
Arg-chloromethylketone (EGR-cmk). The results reveal that mU1 and mU3, despite sharing
an overlapping binding epitope, stabilize two widely different muPA16-243 solution
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conformations. Whereas mU1-bound muPA16-243 displayed increased conformation flexibil-
ity, mU3-bound and EGR-cmk-bound muPA16-243 displayed decreased conformational flexi-
bility in surface-exposed loops surrounding the active site. As the HDXMS results reveals a
functional link between the 70s loop and the active site region, we next investigated if the 70s
loop serves as an exosite during cleavage of the physiological uPA substrate plasminogen. A
kinetic analysis of plasminogen activation by alanine-substituted full-length muPA mutants
revealed that residues Glu73 and Ser74 may be important during plasminogen activation as
KM was significantly increased for the muPA E73A and S74A mutants. Taken together, our
data reveal important mechanistic insight into how long-range conformational changes are
mediated from the 37s and 70s loop to the active site region in muPA thereby providing a
rationale for a possible plasminogen activation mechanism.
Materials and methods
Generation of mU1, mU3, FabmU1 and FabmU3
The generation and characterization of mU1 and mU3 were described previously [16–18]. For
digestion of full-length IgGs, mU1 and mU3 (10 mg) was dialyzed against a cleavage buffer
containing 0.1 M Na2HPO4 and 0.1 M KH2PO4 at pH 7.3. After dialysis, the IgGs were cleaved
by incubation with 15 mM cysteine, 2 mM EDTA and 100 μg papain for 16 h at 37˚C in the
dark. The cleavage reactions where stopped by adding iodoacetamide to 20 mM. The gener-
ated Fab fragments were purified by Protein A affinity chromatography (Ge Healthcare) by
using 50 mM Tris pH 7 as wash buffer and 0.1 M citric acid pH 3.0 as elution buffer. The purity
of the generated Fab fragments was evaluated by SDS-PAGE analysis.
Expression and purification of muPA
Full-length muPA and site-directed alanine mutants were produced in mammalian HEK293
6E suspension cells as previously described [16, 20]. The catalytic serine protease domain of
muPA (muPA16-243) was produced by subcloning cDNA encoding amino acids Gly2 through
Gly243 with a C122A mutation into a T7 derived expression vector with six histidines at the
N-terminus, and expressed as inclusion bodies in E.coli BL21(DE3) (Novagen). For refolding
of muPA16-243 E.coli cells were resuspended in sonication buffer (50 mM Tris pH 8.0; 0.5M
NaCl; 10% (v/v) glycerol; 1 mM beta-mercaptoethanol; 1 mM EDTA) and sonicated on ice
(pulses of 0.8, amplitude 100). The lysed cells were centrifuged at 10,000 RPM, 4˚C for 10 min
and the inclusion bodies were washed in sonication buffer supplemented with 1% (v/v) Triton
X-100. Two additional washes were performed with 0.25% (v/v) and 0% (v/v) Triton X-100
respectively. Finally the inclusion bodies was resuspended in denaturation buffer (50 mM Tris
pH 8.0; 100 mM NaCl; 10 mM β-mercaptoethanol; 6 M urea; 1 mM EDTA) and denatured by
slow stirring at 4˚C. Next the protein concentration was adjusted to below 0.2 mg/mL in dena-
turation buffer and dialysed against 10 L of refolding buffer (50 mM Tris pH 8.0; 1 mM β-mer-
captoethanol; 3 M urea; 10% glycerol) at 4˚C for 22 h. Urea was removed by dialysis against
2x10 L of buffer containing 50 mM Tris pH 8.0 and 10% glycerol at 4˚C for 22 h. After solubili-
zation and refolding muPA was subsequently captured on nickel-sepharose and eluted in 50
mM Bicine pH 8.0; 500 mM NaCl and 400 mM imidazole and dialyzed extensively against PBS
(10 mM Na2HPO4; 1.8 mM KH2PO4; 2.7 mM KCl; 137 mM NaCl; pH 7.4). The protein con-
centration was adjusted to 0.5 mg/mL and incubated with 2.5 μg/mL plasmin at 22˚C for 22h.
The incubation with plasmin ensured correct cleavage between Lys15 and Ile16 to generate the
catalytic domain. Plasmin was removed by passing the sample over a CNBr (GE Healthcare)
activated aprotinin sepharose column. To remove non-activated or misfolded protein benza-
midine-sepharose (GE Healthcare) chromatography was applied. Finally the muPA16-243 active
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catalytic domain was purified by size-exclusion chromatography on a Superdex 75 equilibrated
with PBS supplemented with 300 mM NaCl. Protein purity was verified by SDS-PAGE
analysis.
Hydrogen deuterium exchange mass spectrometry
EGR-cmk-bound muPA16-243 was prepared by incubating muPA16-243 with 10-fold molar
excess of EGR-cmk (Bachem, USA) for 1 h at 22˚C in PBS. Excess EGR-cmk was removed by
dialyzing against 2 L PBS at 4˚C for 16 h. The Fab- muPA16-243 complexes were generated by
incubating 5 μM muPA16-243 with 17 μM FabmU1 or 10 μM FabmU3 for 15 min at 22˚C. The
concentrations of FabmU1 or FabmU3 were estimated based on the equilibrium binding con-
stants between the full-length IgGs and the catalytic domain of muPA as reported in [16, 17]
in order to obtain 99% bound muPA16-243 in the samples.
The HDXMS analysis was performed using a Waters Synapt G2Si System with HDX tech-
nology (Waters Coorporation) and a LEAP HDX PAL autosampler (Leap Technologies). 10
mL D2O buffer was prepared by vacuum centrifugation (SpeedVac SC 100, Savant) of 1 mL
10xPBS and resuspending in 10 mL 99.96% D2O immediately before use. For deuterium
exchange the proteins was mixed with D2O buffer an allowed to incubate for 0, 30 s, 1 min, 2
min or 5 min at 25˚C. The reactions were quenched at pH 2.6 (3 M Guanidine HCl, 0.1% (v/v)
formic acid and 250 mM TCEP) for 1 min at 1˚C and injected on an in-line pepsin column
(Pierce, Inc.). The resulting peptides were captured on a BEH C18 Vanguard pre-column, sep-
arated by analytical chromatography (Acquity UPLC BEH C18, 1.7 μm, 1.0x50 mm, Waters
Corporation) using a 7–85% (v/v) acetonitrile gradient in 0.1% (v/v) formic acid over 7.5 min,
and electrosprayed into the Waters Synapt G2Si quadrupole time-of-flight mass spectrometer.
The mass spectrometer was set to collect data in the Mobility, ESI+ mode; mass acquisition
range of 200–2000 (m/z); scan time 0.4s. Continuous lock mass correction was accomplished
with infusion of leu-enkephalin (m/z (2+) = 556.2771) every 30 s. For peptide identification,
the mass spectrometer was set to collect data in MSE, ESI+ mode instead. The peptides were
identified from triplicate analyses of 12 μM muPA16-243, and data were analysed using PLGS
2.5 (Waters Corporation). Peptides masses were identified using a minimum number of 250
ion counts for low energy peptides and 50 ion counts for their fragment ions. The following
cut-offs were used to filter peptide sequences matches: minimum products per amino acid of
0.2, minimum score of 8, maximum MH+ error of 3 ppm, a retention time RSD of 5%, and the
peptides had to be present in two out of the three identification runs. The peptides identified
in PLGS were analysed in DynamiX 3.0 (Waters Corporation). The relative deuterium uptake
for each peptide was calculated by comparing centroids of the mass envelopes of the deuter-
ated samples with the undeuterated controls (timepoint 0 min).
Chromogenic substrate assays
For evaluating the effect of FabmU1 and FabmU3 on the catalytic activity of muPA16-243, vari-
ous concentrations of FabmU1 (500–0 nM) or FabmU3 (20–0 nM) were incubated with 1 nM
muPA16-243 for 15 min at 37˚C in a buffer containing 10 mM HEPES pH 7.4, 140 mM NaCl
and 0.1% BSA. The chromogenic substrate Pyro-Glu-Gly-Arg-pNa (CS-61(44), Aniara, USA)
was added to a final concentration of 750 μM, and the initial velocities was monitored for 1 h
at 37˚C at an absorbance of 405nm in a microplate reader. For the inhibition of muPA16-243
catalytic activity by mU1, the apparent inhibitory constant (Kappi ) was calculated as described
in [16].
Kinetic analysis of plasminogen activation by full-length muPA was performed using an
indirect chromogenic assay. Plasminogen (24–0 μM), purified from outdated human plasma
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[21], was incubated with full-length muPA or full-length muPA alanine mutants (1 nM) for 30
min at 37˚C. Full-length muPA activity was quenched by adding the muPA competitive inhib-
itor mupain-1-IG (10 μM) [22]. The activity of muPA-generated plasmin was evaluated by
adding the chromogenic substrate S-2251 (0.5 mM), and the initial velocities were monitored
for 1 h at 37˚C at an absorbance of 405nm in a microplate reader. KM, and kcat was determined
by fitting the data using standard Michaelis-Menten kinetics. The experimental procedure was
limited to a maximum plasminogen concentration of 24 μM, as a higher plasminogen concen-
tration resulted in irreversible protein aggregation.
Results
HDXMS analyses were performed with the catalytic serine protease domain of muPA
(muPA16-243) in the following states: ligand free muPA16-243 (apo-muPA16-243), EGR-cmk-
bound muPA16-243, mU1-bound muPA16-243 and mU3-bound muPA16-243. We have recently
reported the HDXMS uptake plots for selected peptides in the muPA16-243 and EGR-cmk
bound muPA16-243 variants [15]. Here, we perform the HDXMS experiments again in order to
provide the complete peptide coverage map and corresponding uptake plots of all pepsin-gen-
erated peptides in muPA16-243 and EGR-cmk bound muPA16-243. The proteins or complexes
were diluted into buffered D2O and the resulting mass increase due to incorporation of deute-
rium was monitored as a function of time (0, 0.5, 1, 2, 5 min). Deuterium incorporation was
localized to various regions of muPA16-243 by mass analysis of peptides produced by pepsin
proteolysis, resulting in the identification of 36 overlapping peptides that together cover 92%
of the muPA16-243 sequence (Fig 1A).
To simplify the HDXMS analysis, we generated Fab fragments of the monoclonal antibod-
ies mU1 and mU3 (Fig 2A). In agreement with previously published results with the intact
full-length monoclonal antibodies, FabmU1 inhibited muPA16-243 hydrolysis of a small chro-
mogenic substrate, whereas FabmU3 stimulated the activity of muPA16-243 by 2-fold (Fig 2B).
We have previously determined the binding epitopes of mU1 and mU3 by alanine scanning
mutagenesis. Whereas residues Gly37c, Pro37e, Pro38, Ser74, Tyr76 and Asn77 in muPA were
determined to be important for the binding of both mU1 and mU3, residues Lys72 and Pro78
were only important for the binding of mU1 (Fig 1A).
Changes in amide exchange of muPA16-243 upon binding of EGR-cmk
We have previously shown how the binding of EGR-cmk to the active site of muPA16-243
decreases deuterium incorporation in peptides containing amino acids that are within contact
distance of (<4Å) of the EGR-cmk molecule [15]. This includes residues in the 180s and 220s
loops. In agreement with this result, we found that the binding of EGR-cmk significantly
reduces deuterium uptake in four peptides that covers the 180s and 220s loops (Fig 3A). One
peptide corresponded to the 180s loop (residues 183–201, MH+ 2149.95Da), and three overlap-
ping peptides corresponded to the 220s loop (residues 202–228, MH+ 2888.48Da; residues
210–228, MH+ 2008.00Da; residues 212–228, MH+ 1863.95Da). Fig 3A shows the deuterium
uptake curves for residues 183–201 and residues 210–228 (the remaining peptides are shown
in S1 Fig). Six peptides corresponded to 90s loop (residues 89-97b, MH+ 1437.70Da; residues
93-97b, MH+ 945.43Da; residues 93–98, MH+ 1016.46Da; residues 93–105, MH+ 1842.86Da;
residues 98–105, MH+ 916.45Da; residues 99–105, MH+ 845.41Da). Somewhat surprisingly
no differences in deuterium incorporation were observed in any of the 90s loop peptides
despite the fact that residues Leu97b and Tyr99 have been shown to be important in substrate
recognition [23] (S1 Fig).
Modulation of structural dynamics in uPA
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Four peptides corresponding to the new N-terminal sequence produced by plasmin were
identified by the analysis. Although all amino acids in the N-terminal sequence are more than
4 Å away from the EGR-cmk molecule, decreased deuterium incorporation upon EGR-cmk
binding was observed in all four peptides. Whereas the peptide covering the N-terminal Ile-16
(residues 16–21, MH+ 621.32Da) only showed a slight reduction in deuterium incorporation,
the decreased deuterium incorporation in the three peptides covering the following stretch of
Fig 1. HDXMS coverage map. (A) The X-ray crystal structure of the catalytic domain of muPA16-243 in its active
conformation (PDB ID 5LHR). Important regions in muPA16-243 are highlighted by colors (A); light-pink for the
activation loop, light blue for the 90s loop, yellow for the 110s loop, orange for the 140s loop, gray for the 170s loop,
brown for the β9-strand, red for the 180s loop and teal for the 220s loop. Residues in the 37s and 70s that are in
common for the mU1 and mU3 binding epitopes are highlighted in red and shown as sticks. Resides that are unique to
the mU1 binding epitope are highlighted in cyan and shown as sticks. (B) The HDXMS coverage map. Gray bars
underneath the muPA16-243 sequence show the pepsin-generated peptides. Peptide masses for each peptide are
indicated on the bar.
https://doi.org/10.1371/journal.pone.0192661.g001
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amino acids was more pronounced (Fig 3B) (residues 22–30, MH+ 1149.52; residues 22–32,
MH+ 1291.59Da; residues 22–33, MH+ 1404.67Da). No other significant changes in amide
exchange were observed upon EGR-cmk binding in the reminder of the N-terminal β-barrel
(S1 Fig).
Five peptides corresponded to the 140s loop (residues 136–148, MH+ 1401.58Da; residues
138–148, MH+ 1169.53Da; residues 149–157, MH+ 1169.63Da; residues 149–159, MH+
1355.73Da; residues 150–159, MH+ 1192.67Da). The 140s loop is known as a very flexible loop
in trypsin-like serine proteases, and it has been shown that binding of active site ligands allo-
sterically reduces the conformational flexibility of this loop [24]. In good agreement with this
notion, our results revealed that all five peptides covering the 140s loop showed decreased deu-
terium incorporation upon binding of EGR-cmk (Figs 3C and S1).
We have previously shown that binding of EGR-cmk to the active site of muPA16-243 allo-
sterically affects the conformational flexibility of the β9-strand and 170s loop [16]. In agree-
ment with our previous findings, our HDXMS results showed that the binding of EGR-cmk
reduced deuterium incorporation in both peptides covering the 170s loop (residues 160–175,
MH+ 160–175; residues 163–175, MH+ 1794.72Da) and in the single peptide covering the
β9-strand (residues 176–182, MH+ 884.43) (Figs 3D and S1).
Changes in amide exchange of the 37s and 70s loops in muPA16-243 upon
binding of FabmU1 and FabmU3
Given the high sequence coverage and extensive changes throughout muPA16-243 induced by
EGR-cmk binding, HDXMS was expected to reveal the differences in conformational states
Fig 2. Generation and characterization of FabmU1 and FabmU3. (A) SDS-PAGE analysis of the whole IgG and
papain-cleaved IgG after protein A affinity chromatography. (B) The effect of FabmU1 (left) and FabmU3 (right) to
the catalytic activity of muPA16-243 towards the small chromogenic substrate Glu-Gly-Arg-pNA (CS-61(44)). Error
bars, s.d. (n = 3 independent measurements).
https://doi.org/10.1371/journal.pone.0192661.g002
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accounting for the opposite functional effect of mU1 and mU3 on the catalytic activity of
muPA16-243. When compared with apo- muPA16-243 the HDXMS results revealed decreased
deuterium incorporation in three peptides covering the FabmU1 and FabmU3 binding epi-
topes in the 37s and 70s loops (residues 34–40, MH+ 1309.65Da; residues 65–83, MH+
2163.04Da; residues 68–83, MH+ 1801.84Da) (Figs 4 and S2). The decreased exchange at the
binding site is likely due to a combination of decreased surface solvent accessibility due to for-
mation of the Fab binding interface as well as perhaps additional localized dampening of loop
dynamics. The dampening effect was observed by a reduced exchange in the 110s loop
Fig 3. Relative deuterium uptake plots for peptides in apo-muPA16-243 versus EGR-cmk-bound muPA16-243. The
figure shows uptake plots from peptides covering (A) the active site regions 180s and 220s loops, (B) the activation
loop, (C) the 140s loop, (D) the β9-strand and the 170s loop. Peptide sequence, masses and residues numbers are
shown for each peptide. The Y-axis is scaled to show the theoretical maximum deuterium uptake of the corresponding
peptide. Error bars, s.d. (n = 3 independent measurements).
https://doi.org/10.1371/journal.pone.0192661.g003
Modulation of structural dynamics in uPA
PLOS ONE | https://doi.org/10.1371/journal.pone.0192661 February 8, 2018 8 / 16
(residues 106–120, MH+ 2075.10Da) (S2 Fig), which was not identified as a part of the mU1
and mU3 binding epitopes in the alanine scanning mutagenesis [16, 17].
Difference in amide exchange of the muPA16-243 active site region upon
binding of FabmU1 or FabmU3
When compared to apo- muPA16-243, the binding of FabmU1 to muPA16-243 caused increased
deuterium incorporation in several regions of muPA16-243 whereas FabmU3 caused slightly
decreased exchange in many of these same regions. The peptides corresponding to the 180s
and 140s loops are examples of such opposing effects of the two Fab fragments (Fig 5A and
5B). Interestingly, the peptide covering the 180s loop harbors the catalytic Ser195 and residues
forming the S1 specificity pocket (Asp189) and the oxyanion hole (Gly193 and Ser195). In
addition, FabmU1 caused an increase in amide exchange of peptides covering several loops
surrounding the muPA16-243 active site, including five peptides in the 140s loop (Figs 5B and
S2), two peptides in the 170s loop (Figs 5C and S2) and in the single peptide covering the
β9-strand (Fig 5D). Oppositely to FabmU1, FabmU3 caused a decreased deuterium uptake in
the same peptides (Fig 5B, 5C and 5D). FabmU1 binding also caused increased deuterium
incorporation in both peptides corresponding to the 220s loop, whereas FabmU3 had no sig-
nificant effect on this region (Figs 5E and S2).
The binding of FabmU1 and FabmU3 resulted in complex differences in amide exchange
in different regions of the 90s loop in muPA16-243. Binding of both FabmU1 and FabmU3
caused decreased deuterium incorporation in the peptide corresponding to residues 93–98 of
the 90s loop (MH+ 1016.46Da) (S2 Fig). However, FabmU1 and FabmU3 had opposite effects
on deuterium incorporation in the peptide corresponding to residues 93–105 (MH+
1842.86Da) (S2 Fig).
A possible role of the muPA16-243 70s and 140s loops in plasminogen
activation
The 140s loop in the uPA homologue tissue-type plasminogen activator (tPA) has previously
been identified as an important exosite for recognition of the physiological uPA substrate,
plasminogen [25]. As the 70s loop is in the vicinity of the 140s loop, and since our HDXMS
results showed that binding of FabmU1 or FabmU3 to the 70s loop affected the conforma-
tional flexibility of the 140s loop differently, we now hypothesized that the 70s loop may be
important for the recognition of plasminogen either directly or indirectly by controlling the
conformational flexibility of the 140s loop. To investigate this hypothesis, we generated a panel
Fig 4. Relative deuterium uptake plots for peptides in apo- muPA16-243 versus FabmU1:muPA16-243 and FabmU3:
muPA16-243. The figure shows uptake plots from peptides covering the 37s and 70s. Peptide sequence, masses and
residues numbers are shown for each peptide. The Y-axis is scaled to show the theoretical maximum deuterium uptake
of the corresponding peptide. Error bars, s.d. (n = 3 independent measurements).
https://doi.org/10.1371/journal.pone.0192661.g004
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of full-length muPA alanine substitution mutants and evaluated their kinetic parameters for
plasminogen activation and hydrolysis of the small chromogenic substrate Glu-Gly-Arg-pNA
(Tables 1 and 2). The measured KM and kcat for plasminogen activation by full-length muPA
were 9.8 μM and 3.5 s-1 respectively. Mutation of Lys72, Tyr76, Asn77 and Pro78 to Ala caused
small decreases in KM for plasminogen activation and a slight but insignificant increase in the
kcat. Mutation of Glu73 and Ser74 to Ala strongly affected plasminogen activation by causing a
more than 2-fold increase in KM (24.6 μM and 22 μM respectively). However, a significant
decrease in kcat was only observed for the Glu73 to Ala mutation but not for the Ser74 to Ala
mutation (Table 1). The most dramatic effect on plasminogen activation was observed upon
mutation of Tyr149 to Ala, which caused a 60-fold decrease in kcat without affecting KM
(Table 1). Interestingly, the Tyr149 to Ala mutation showed opposite effects on the kinetics of
hydrolysis of the small chromogenic substrate, for which an increase in kcat and a decrease in
KM were observed (Table 2). Alanine substitutions in the 70s loop largely did not affect KM
and kcat for the hydrolysis of the small chromogenic substrate. In summary, these results show
that residues in the 70s loop are important for the recognition of plasminogen, but not for
cleavage of small chromogenic substrates.
Fig 5. Relative deuterium uptake plots for peptides in apo-muPA16-243 versus FabmU1:muPA and FabmU3:
muPA. The figure shows uptake plots from peptides covering (A) the 180s loop, (B) the 220s loop, (C) the 140s loop,
(D) the 170s loop and the β9-strand. Peptide sequence, masses and residues numbers are shown for each peptide. The
Y-axis is scaled to show the theoretical maximum deuterium uptake of the corresponding peptide. Error bars, s.d.
(n = 3 independent measurements).
https://doi.org/10.1371/journal.pone.0192661.g005
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Discussion
When compared to apo- muPA16-243, EGR-cmk-bound muPA16-243 showed decreased amide
exchange in regions corresponding to the N-terminal activation loop, the 140s, the 180s, and
the 220s loops. The four loops are interconnected through three patches of polar interaction
networks (patch I, II and III) (Fig 6). In muPA16-243, patch I interconnects the N-terminal base
of the 140s loop with the 180s loop (Fig 6). Residues Lys192 and Asp194, which is adjacent to
the oxyanion hole residues (Gly193 and Ser195), are in direct contact with the residues Gly142
and Lys143 of the 140s loop. Patch II interconnects the C-terminal base of the 140s loop to the
N-terminal activation loop. Residues Leu155, Lys156 and Met157 of the 140s loop are in direct
contact with residues Ile16, Gly18, Glu20 and Thr22 in the N-terminal sequence (Fig 6). Patch
III interconnects the 140s loop and the 220s loop. Glu146 contacts Glu222, which is in vicinity
of residues of the S1 specificity pocket (Gly218) (Fig 6). Our HDXMS results clearly show that
the N-terminal sequence, the 140s, the 180s, and the 220s loops is highly dynamic in apo-
muPA16-243. Binding of EGR-cmk, however, dampens exchange throughout the loops presum-
ably by strengthening the interconnectivity of stabilizing interactions in patches I, II and III.
Importantly, our HDXMS data revealed a relatively high amide exchange level (71%) in the
peptide covering the N-terminal Ile16 suggesting that Ile-16 may be mostly solvent-exposed.
This observation is in good agreement with the notion that apo- muPA16-243 crystallizes in a
conformation with a solvent-exposed Ile16 [15].
Table 1. Kinetic analysis for plasminogen activation by full-length muPA and variants.
KM (μM) kcat (s-1) kcat/KM (μM-1 s-1)
Full-length muPA 9.8 ± 1.1 3.5 ± 0.9 0.4 ± 0.1
Full-length muPA K72A 3.1 ± 0.9 5.0 ± 1.9 1.6 ± 0.1
Full-length muPA E73A¶ 24.6 ± 2.8 1.3 ± 0.1 0.05 ± 0.01
Full-length muPA S74A¶ 22.0 ± 3.8 3.5 ± 0.6 0.16 ± 0.01
Full-length muPA Y76A 5.0 ± 2.4 5.1 ± 1.5 1.2 ± 0.7
Full-length muPA N77A 5.1 ± 0.8 4.8 ± 0.8 1.0 ± 0.01
Full-length muPA P78A 3.9 ± 1.1 5.2 ± 1.2 1.3 ± 0.1
Full-length muPA Y149A 12.0 ± 2.7 0.06 ± 0.04  0.0053 ± 0.0045
Significantly different from the corresponding value determined for full-length muPA (p < 0.05)–student’s t-test.
¶ The KM is equal to the highest plasminogen concentration used (24 μM).
https://doi.org/10.1371/journal.pone.0192661.t001
Table 2. Kinetic analysis for hydrolysis of a chromogenic substrate CS-61(44) by full-length muPA and variants.
KM (μM)
S-2444
kcat (s-1)
S-2444
kcat/KM (μM-1 s-1)
Full-length muPA 2600 ± 200 10.9 ± 2.3 0.004 ± 0.001
Full-length muPA K72A 2600 ± 200 6.6 ± 1.4 0.003 ± 0.001
Full-length muPA E73A 1860 ± 270 11.7 ± 1.8 0.006 ± 0.001
Full-length muPA S74A 2900 ± 100 12.8 ± 4.3 0.004 ± 0.002
Full-length muPA Y76A 2600 ± 100 9.0 ± 1.2 0.004 ± 0.001
Full-length muPA N77A 3800 ± 115 8.6 ± 1.8 0.002 ± 0.001
Full-length muPA P78A 2500 ± 100 9.7 ± 1.6 0.004 ± 0.001
Full-length muPA Y149A 1400 ± 320 39 ± 10 0.03 ± 0.01
Significantly different from the corresponding value determined for full-length muPA (p < 0.05)–student’s t-test.
https://doi.org/10.1371/journal.pone.0192661.t002
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EGR-cmk-bound muPA16-243 also showed a decreased amide exchange level in the
β9-strand and 170s loops when compare to apo- muPA16-243. We have recently showed that
the 170s loop in muPA exists in equilibrium between open and closed conformations [15].
The decreased amide exchange in the 170s loop in EGR-cmk-bound muPA16-243 shows that
EGR-cmk stabilizes the closed conformation. Since the β9-stand is tucked away underneath
the 170s loop, the closed 170s loop conformation is also expected to protect the β9-stand from
amide exchange. The active site region of muPA is interconnected to the 170s loop through
two patches of polar interaction networks (patch IV and V). In patch IV Tyr172 of the 170s
loop forms hydrogen bonds with the backbone N-atom of Arg217 and the carbonyl O-atom of
Pro-225 from the 220s loop (Fig 6). Since Arg217 is part of the S3 substrate binding pocket
Fig 6. The allosteric pathway in muPA. Structural representation of muPA16-243 in complex with EGR-cmk (The model was prepared using PDB ID 5LHQ and
5LHR). The mU1 and mU3 binding site in the 37s and 70s loops is indicated by an orange arrow. Regions identified by the HDXMS analysis to be affected
differently by FabmU1 and FabmU3 are highlighted by colored boxes; black: 180s loop of the active-site region, grey: the N-terminal base of the 140s loop, red: the
C-terminal base of the 140s loop, brown: the 220s loop, blue: the β9-strand, purple: the 170s loop. The colored boxes are also displayed as zooms of Patch I: The
interaction network between the N-terminal base of the 140s loop and residues of the oxyanion hole; Patch II: The interaction network between the C-terminal base
of the 140s loop and residues of the N-terminal activation loop; Patch III: The interactions between the 140s loop and the 220s loop; Patch IV: The interaction
between the 170s loop and the 220s loop; Patch V: The hydrophobic interaction between the 170s loop and the 220s loop. Patch VI The 70s/140s interaction
network. In all figures interacting residues are shown as sticks and black dashed lines represent potential hydrogen bonds. The figure was prepared using PyMOL
version 1.7.4.0.
https://doi.org/10.1371/journal.pone.0192661.g006
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and positioned next to Gly218, which interacts directly with the Arg-moiety of EGR-cmk, it
is reasonable to assume that EGR-cmk stabilizes the closed 170s loop conformation by stabi-
lizing the Tyr172-Arg217 interaction. In patch V, the stabilizing effects of EGR-cmk on the
170s loop may propagate through Trp215. Trp215 is buried in a hydrophobic pocket created
by residues in the 170s and 220s loops (Tyr172, Ile176, Met180 and Val227) and the β12-
strand (Val227) (Fig 6). Since the Trp215 is involved in substrate recognition together with
Gly216 as a part of the S2 binding pocket, the stabilizing effect of EGR-cmk to Trp215 may
secure its position in the hydrophobic pocket further stabilizing the 170s loop in the closed
conformation.
In X-ray crystal structures of trypsin-like serine proteases in their active conformation, resi-
dues in the 70s loop are forming multiple hydrogen bonds with residues at the C-terminal
stem of the 140s loop. In muPA the carbonyl group of Ser-71 is within hydrogen bonding dis-
tance of the backbone N-atom of Leu-155 and the side chain N-atom of Asn-154. Further-
more, the backbone N-atom of Glu-73 contacts the backbone carbonyl O-atom of Lys-153,
whereas the side chain Oε1 atom of Glu-73 contacts the side chain N-atom of Lys-153 (Fig 6).
In addition, the OH-group of Ser74 stabilizes the side chain of Glu73 in the groove between
the 70s and 140s loop by forming a hydrogen bond to the Oε1 moiety of Glu73. Although the
exact binding mechanism of FabmU1 and FabmU3 must await structural characterization, it is
interesting to surmise that the hydrogen bonds between the 70s and 140s loops (patch VI) may
be destabilized in the FabmU1-bound muPA16-243 conformation, but stabilized in FabmU3-
bound muPA16-243. This hypothesis readily explains the different functional effects of mU1
and mU3 to the muPA16-243 activity, as the 140s loop is interconnected with the active site
region through patch I, II and III. Our HDXMS data strongly supports this view by showing
that binding of FabmU1 to muPA16-243 caused an increase in amide exchange in the 140s,
170s, 180s, 220s loops and the β9-stand, whereas FabmU3 binding to muPA16-243 caused
decreased amide exchange. Thus, mU1 stabilizes a highly dynamic, inactive muPA16-243 con-
formation, whereas mU3 stabilizes a less dynamic, active muPA16-243 conformation.
The loop corresponding to the 70s loop in the coagulation protease, thrombin, is part of the
regulatory anion binding exosite 1 (ABE1). Binding of ligands, cofactors and substrates to
ABE1 allosterically regulates the activity and function of the active site in thrombin [10, 26].
The 70s loop is also known as an activity regulatory divalent cation binding site in some tryp-
sin-like serine protease including the coagulation factors VIIa and X, trypsin and the kalli-
krein-related protease 4 [27–31]. Moreover, the 70s loop has been shown to participate in
allosteric networks in trypsin-like serine proteases by interconnecting the 70s loop to the N-
terminal activation loop, the 90s loop and to the 140s loop [32–34].
Although the plasminogen-activation system has been thoroughly studied for more than
50 years, the mechanism of plasminogen activation has remained largely obscure. This is due to
the lack of structural information about the plasminogen-plasminogen activator (tPA or uPA)
complexes. Here, we went in another direction and combined the information from the
HDXMS with a kinetic analysis to propose a model for muPA-mediated plasminogen activation.
In agreement with previous results in which the binding interface between tPA and plasminogen
was mapped, we found that the 140s loop is important in plasminogen activation by muPA, find-
ing that the Tyr149 to Ala mutation caused a marked decrease in kcat. Interestingly, the side-
chain moiety of Tyr149 is solvent-exposed and positioned distantly from the surrounding sur-
face-exposed loops in muPA (Fig 6). The observed change in kcat but not KM suggests that
Tyr149 play an important role in positioning of plasminogen as a substrate for efficient cleavage
by muPA. Our analysis further revealed an important role of the 70s loop in muPA for plasmino-
gen activation, as mutation of Glu73 and Ser74 to Ala caused an increase in KM. Since the KM for
hydrolysis of the small chromogenic substrate remained unchanged for the Glu73 and Ser74 to
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Ala mutants, our data suggests that the 70s loop forms an important secondary exosite of interac-
tion between muPA and plasminogen. Interestingly, the HDXMS data showed that binding of
ligands, such as mU1 and mU3, to the 37s and 70s loops may stabilize more or less dynamic
muPA16-243 conformations. Thus, the HDXMS and kinetic results strongly supports a model of
plasminogen activation in which plasminogen primes its own activation through binding to the
70s and/or 140s loops thereby stabilizing muPA in a less dynamic active conformation.
The observation that mU1 stabilizes an inactive muPA16-243 conformation, which by many
criteria is similar to a muPA conformation recently described in a X-ray crystal structure of
apo- muPA16-243 is of significant importance since mU1 has been shown to inhibit muPA
dependent processes in vivo such as reduction of atherosclerosis in mice [15, 18, 19]. Collec-
tively, these results strongly suggest that a muPA conformation with a highly distorted C-ter-
minal β-barrel may exist in vivo under normal or pathological conditions. Thus, targeting
inactive uPA conformations with allosteric agents such as mU1 represents an attractive strat-
egy for intervention with the pathophysiological activities of uPA.
Supporting information
S1 Fig. Relative deuterium uptake. Uptake plots for the 28 peptides not shown in the main
text covering apo-muPA16-243 (blue dots) and muPA16-243:EGR-cmk (black dots). Peptide
sequence, masses and residues numbers are shown for each peptide. The Y-axis is scaled to
show the theoretical maximum deuterium uptake of the corresponding peptide. Error bars, s.
d. (n = 3 independent measurements).
(TIF)
S2 Fig. Relative deuterium uptake. Uptake plots for the 28 peptides not shown in the main
text covering apo-muPA16-243 (blue dots), muPA16-243:FabmU1 (orange dots) and muPA16-243:
FabmU3 (green dots). Peptide sequence, masses and residues numbers are shown for each
peptide. The Y-axis is scaled to show the theoretical maximum deuterium uptake of the corre-
sponding peptide. Error bars, s.d. (n = 3 independent measurements).
(TIF)
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